** Shares of cancer therapy developer Greenwich LifeSciences GLSI.O rise 18.8% to $11 premarket
** GLSI says its experimental therapy, GLSI-100, to prevent breast cancer recurrences showed an increased immune response over time in patients during a late-stage study
** The therapy creates an immune response over time, as measured by the increasing injection site reactions with increased vaccinations
** Company says in the preliminary data, the patients reported immune response increased over time from baseline through the 4th- to 6th-month vaccinations
** As of last close, stock has fallen 51.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.